Get started
Akebia Therapeutics, Inc.Akebia Therapeutics, Inc.Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFs
Full chart
Full chart

Compare with Akebia Therapeutics, Inc.



Key stats


Market capitalization
‪233.88 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.1110 USD
Net income (FY)
‪−5.34 M‬ USD
Revenue (FY)
‪236.20 M‬ USD
Shares float
‪271.06 M‬
Beta (1Y)
0.05

Latest earnings


Last report date
Aug 5, 2026
Report period
Q2 2026
EPS
−0.03 USD
Revenue
‪49.13 M‬ USD
Earnings call summary

Vafseo achieved strong revenue and patient growth, driven by positive VOICE trial results and expanded adoption across dialysis organizations. Pipeline assets advanced in rare kidney diseases, while AURYXIA revenues declined due to competition. Cash position supports operations for at least two years.

Employees


Employees (FY)
194
Change (1Y)
+13+7.18%
Revenue / Employee (1Y)
‪1.22 M‬ USD
Net income / Employee (1Y)
‪−27.55 K‬ USD

Details


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
John P. Butler
Website
akebia.com
Headquarters
Cambridge
Founded
2007
IPO date
Mar 19, 2014
ISIN
US00972D1054
CUSIP
00972D105
FIGI
BBG000R33R00
Identifiers
ISIN US00972D1054
CFI code
ESVUFR
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice Jr., Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


IWO
iShares Russell 2000 Growth Fund
Weight0.01%
Market value‪1.84 M‬
FESM
Fidelity Enhanced Small Cap Core ETF
Weight0.02%
Market value‪1.56 M‬
VHT
Vanguard Health Care ETF
Weight0.00%
Market value‪860.03 K‬
IWC
iShares Microcap ETF
Weight0.05%
Market value‪767.05 K‬
159502
Harvest S&P Biotechnology Select Industry ETF
Weight0.17%
Market value‪536.55 K‬
SMLF
iShares U.S. Small-Cap Equity Factor ETF
Weight0.01%
Market value‪535.20 K‬
GSSC
GS ActiveBeta U.S. Small Cap Equity ETF
Weight0.03%
Market value‪378.63 K‬
VTWG
Vanguard Russell 2000 Growth ETF
Weight0.02%
Market value‪284.38 K‬
SBIO
ALPS Medical Breakthroughs ETF
Weight0.12%
Market value‪261.79 K‬
QQQS
Invesco NASDAQ Future Gen 200 ETF
Weight0.42%
Market value‪95.11 K‬
FEAC
Fidelity Enhanced U.S. All-Cap Equity ETF
Weight0.00%
Market value100.51

Explore more ETFs 

Frequently asked questions


The current price of AKBA is 0.8811 USD — it has increased by 2.67% in the past 24 hours. Watch Akebia Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Akebia Therapeutics, Inc. stocks are traded under the ticker AKBA.
AKBA stock has fallen by −33.85% compared to the previous week, the month change is a −39.41% fall, over the last year Akebia Therapeutics, Inc. has showed a −73.78% decrease.
We've gathered analysts' opinions on Akebia Therapeutics, Inc. future price: according to them, AKBA price has a max estimate of 6.00 USD and a min estimate of 1.00 USD. Watch AKBA chart and read a more detailed Akebia Therapeutics, Inc. stock forecast: see what analysts think of Akebia Therapeutics, Inc. and suggest that you do with its stocks.
AKBA reached its all-time high on Jun 20, 2014 with the price of 31.0000 USD, and its all-time low was 0.2410 USD and was reached on Oct 24, 2022. View more price dynamics on AKBA chart.
See other stocks reaching their highest and lowest prices.
AKBA stock is 3.29% volatile and has beta coefficient of 0.05. Track Akebia Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Akebia Therapeutics, Inc. there?
Today Akebia Therapeutics, Inc. has the market capitalization of ‪240.11 M‬, it has increased by 0.79% over the last week.
Yes, you can track Akebia Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Akebia Therapeutics, Inc. is going to release the next earnings report on Oct 29, 2026. Keep track of upcoming events with our Earnings Calendar.
AKBA earnings for the last quarter are −0.03 USD per share, whereas the estimation was −0.04 USD resulting in a 28.57% surprise. The estimated earnings for the next quarter are −0.04 USD per share. See more details about Akebia Therapeutics, Inc. earnings.
Akebia Therapeutics, Inc. revenue for the last quarter amounts to ‪49.13 M‬ USD, despite the estimated figure of ‪48.85 M‬ USD. In the next quarter, revenue is expected to reach ‪48.23 M‬ USD.
AKBA net income for the last quarter is ‪−8.91 M‬ USD, while the quarter before that showed ‪−9.05 M‬ USD of net income which accounts for 0.00% change. Track more Akebia Therapeutics, Inc. financial stats to get the full picture.
No, AKBA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 12, 2026, the company has 194 employees. See our rating of the largest employees — is Akebia Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Akebia Therapeutics, Inc. EBITDA is ‪−11.63 M‬ USD, and current EBITDA margin is 10.49%. See more stats in Akebia Therapeutics, Inc. financial statements.
Like other stocks, AKBA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Akebia Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Akebia Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Akebia Therapeutics, Inc. stock shows the sell signal. See more of Akebia Therapeutics, Inc. technicals for a more comprehensive analysis.